IL4R and alexithymia: Probably, because patients with alexithymia had a greater severity of the disease at the baseline than patients without alexithymia (EASI = 30.85 vs 23.50), treatment with anti–IL-4Rα for 16 weeks was most effective for them in reducing itching, and this positively affected their QoL.